Oral Delivery Articles & Analysis
27 news found
These oral thin film manufacturing methods are redefining the ways in which active pharmaceutical ingredients (APIs) are incorporated into convenient, effective delivery systems. Oral thin films present a novel approach in drug delivery, offering ease in administration without the need for water and reducing risks associated with ...
In the ever-evolving pharmaceutical landscape, CD Formulation is emerging as a pioneer in the development of oral thin film (OTF) delivery systems. These cutting-edge drug delivery technologies enhance therapeutic efficiency and patient compliance, offering a versatile alternative to conventional tablets and capsules. ...
With a relentless commitment to delivering innovative solutions and excellent customer service, CD Formulation has built a strong reputation in the industry, particularly in fields like Transdermal Patches Drug Delivery System, Oral Thin Films Drug Delivery, Microneedle Technology, Microsphere Development, etc. ...
Recently, CD Formulation further strengthened its role as a drug delivery expert by demonstrating its expertise in the development of cutting-edge CAR-T and CAR-NK cells for drug delivery systems. ...
Funding from the BARDA Division of Research, Innovation, and Ventures (DRIVe) enabled the company to reformulate LMN-301, previously developed for oral delivery, and to evaluate its potential as an anti-viral therapeutic delivered to the respiratory tract, the primary site of SARS-CoV-2 infection. ...
The active pharmaceutical ingredient is not well absorbed via oral delivery and is formulated as a once-daily TDS patch to increase bioavailability and provide a slow and steady supply of the drug over the course of 24 hours. ...
The published research details how this platform was used to express a malaria protein antigen that can be delivered intranasally and later boosted with a simple oral booster. Treated mice demonstrate protection against subsequent malaria challenge. ...
(NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced findings from its formulation study for CTx-2103, the Company’s asset for the management of anxiety-related disorders. ...
Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today positive results from high-level data from its Phase 1 study of STAR-LLD, evaluating the pharmacokinetics (PK) and safety of the Company’s continuous delivery lenalidomide program. The Phase 1 study met all of its primary and secondary endpoints; in all subjects ...
Bypassing the blood-brain barrier (BBB) and nose-to-brain delivery have long been the elusive “holy grail” for the treatment of CNS diseases. ...
Rani Therapeutics Holdings, Inc. recently announced the development of a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule. ...
In addition, funds will support the expansion of Locus’ discovery platform engine and enhancement of its in-house manufacturing capability to support oral solid dose delivery of its products. “Locus’ novel scientific approach has the potential to fundamentally change the way bacterial diseases are treated. ...
Panag will work with True North's product team to integrate this technology and develop a line of hemp-derived CBD formulations, for True North and its partners to commercialize through their existing distribution relationships in both the medical and recreational markets in Canada About the Technology In developing these products, the Panag team is using Tetra's liposome encapsulated ...
Such SG EZ-be Pod is a small, wearable infusion device that can be programmed for a wide range of medications and delivery profiles, including at-home delivery. This subcutaneous drug delivery system is the flagship for Bexson’s proprietary ketamine formulation, BB106, and leverages Stevanato Group’s existing technology and broad ...
The publication, “Development of Spirulina for the Manufacture and Oral Delivery of Protein Therapeutics” is accessible online here. ...
Rani Therapeutics has developed an oral biologics device, named RaniPill HC, for the delivery of biologics. The new device is capable of delivering a drug payload of up to or more than 500% higher compared to the company’s current oral biologics capsule. A preclinical study of RaniPill HC has been conducted by the company, in which the ...
(NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. ...
” The patent supports Oramed’s oral protein delivery platform technology which underlies its lead drug candidate ORMD-0801 now in pivotal Phase 3 studies and positioned to potentially be the first oral insulin capsule on the market. ...
(Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that its subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax’s ...
Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax’s oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ...